Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population

Yi-Shuo Wu,1,2* Xiao-Bo Wu,1,2* Ning Zhang,1,2 Guang-Liang Jiang,1,2 Yang Yu,5 Shi-Jun Tong,1,2 Hao-Wen Jiang,1,2 Shan-Hua Mao,1,2 Rong Na,2,3 Qiang Ding,1,2

This study was performed to evaluate prostate-specific antigen-age volume (PSA-AV) scores in predicting prostate cancer (PCa) in a Chinese biopsy population. A total of 2355 men who underwent initial prostate biopsy from January 2006 to November 2015 in Huashan Hospital were recruited in the current study. The PSA-AV scores were calculated and assessed together with PSA and PSA density (PSAD) retrospectively. Among 2133 patients included in the analysis, 947 (44.4%) were diagnosed with PCa. The mean age, PSA, and positive rates of digital rectal examination result and transrectal ultrasound result were statistically higher in men diagnosed with PCa (all P < 0.05). The values of area under the receiver operating characteristic curves (AUCs) of PSAD and PSA-AV were 0.864 and 0.851, respectively, in predicting PCa in the entire population, both performed better than PSA (AUC = 0.805; P < 0.05). The superiority of PSAD and PSA-AV was more obvious in subgroup with PSA ranging from 2.0 ng ml\(^{-1}\) to 20.0 ng ml\(^{-1}\). A PSA-AV score of 400 had a sensitivity and specificity of 93.7% and 40.0%, respectively. In conclusion, the PSA-AV score performed equally with PSAD and was better than PSA in predicting PCa. This indicated that PSA-AV score could be a useful tool for predicting PCa in Chinese population.

Asian Journal of Andrology (2018) 20, 324–329; doi: 10.4103/aja.aja_81_17; published online: 6 February 2018

Keywords: age; China; prostate cancer; prostate-specific antigen; volume

INTRODUCTION
Prostate cancer (PCa) is the second most common cancer and a leading cause of death among men in the world, with an estimated incidence of 903 500 cases, causing 258 400 death every year.1 By the year of 2030, an estimated 500 000 men will die of PCa.2 The incidence of PCa in China is still relatively low; however, it has risen rapidly over the past decades.3,4

Serum prostate-specific antigen (PSA) is the most widely used biomarker for PCa screening since its introduction into clinical practice. It is recommended by the Chinese Urological Association (CUA) guideline that men over 50 years with lower urinary tract symptoms or men over 45 years with a family history of PCa should undergo PSA screening annually.1 However, since PSA is an organ-specific rather than disease-specific biomarker, the widely application of PSA in PCa screening has revealed its low specificity at its usual cutoff (e.g., 4.0 ng ml\(^{-1}\)) and led to overdiagnosis.5,6 Recently, various strategies were introduced to improve the sensitivity and specificity of PSA.7–11 Clinical variables including PSA, prostate volume (PV), and age were proved to be independent predictors of positive prostate biopsy findings.12–17

In order to combine PSA, PV, and age in a simple and reasonable way, Patel et al.18 developed a novel algorithm that incorporates them into a single score for PCa prediction, called PSA-age volume (PSA-AV) score. This score is calculated by multiplying the age and PV and then dividing the total by the prebiopsy PSA. According to their internal and external validation studies, a lower PSA-AV correlated with a greater cancer risk and a PSA-AV score of 700 was recommended in ruling out cancer in younger patients and patients with small prostates, and in ruling in cancer in older patients and patients with large prostates. This result indicated that PSA-AV could be a more useful tool than PSA in particular groups. Later, in one study, the predictive effect of PSA-AV was similar to PSA density (PSAD) and another study showed that the predictive effect for a PSA-AV score of 700 was similar to a PSA cutoff of 4.0 ng ml\(^{-1}\).19,20

Whether PSA-AV could outperform PSAD or PSA was still uncertain based on the previous studies. In addition, according to studies in Chinese population, the clinical feature of Chinese biopsy population differed from that of Caucasians and Africans (normally with higher PSA level and elder age).21–25 Therefore, it is worth evaluating the predictive utility of PSA-AV and investigating an appropriate cutoff in Chinese population.

PATIENTS AND METHODS
Study population and sample collection
A total of 2355 men who underwent initial prostate biopsy from January 2006 to November 2015 in Huashan Hospital (a Tertiary Health Institutes in Shanghai, China) were retrospectively included in the current study. All the clinical information was collected before biopsy.

*These authors contributed equally to the work.
Correspondence: Dr. Q Ding (qiangd_urology126.com) or Dr. R Na (narong.hs@gmail.com)
Received: 6 July 2017; Accepted: 30 November 2017
information of age, PSA, or PV. The characteristics of tertiary health institutes in China were described in our previous study.21

All the patients in the current study underwent an ultrasound-guided transperineal prostate biopsy with 6 cores before October 2007 or 10 cores thereafter. The indications for prostate biopsy at our institute were: (1) total prostate-specific antigen (tPSA) >4.0 ng ml⁻¹; (2) tPSA <4.0 ng ml⁻¹, with a suspicious free prostate-specific antigen (fPSA)/tPSA <0.16 or PSAD >0.15 (PSAD = tPSA/PV; PV [ml] = height [cm] × length [cm] × width [cm] × 0.52); (3) positive findings from a digital rectal examination (DRE) with any level of tPSA; and (4) positive findings from imaging techniques such as transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI), with any level of tPSA. All blood samples were collected prior to biopsy and measured by the Department of Clinical Laboratory in Huashan Hospital for tPSA and fPSA. Prostate specimens were diagnosed by pathologists from the Pathology Department of Huashan Hospital. The current study was approved by the Institutional Review Board of Huashan Hospital, Fudan University, Shanghai, China. Written informed consent was obtained from all patients for their participation in the study.

Statistical analysis

The baseline characteristics of the study cohort and its subgroup with PSA ranging from 2.0 ng ml⁻¹ to 20.0 ng ml⁻¹ were described as two groups (PCa patients and non-PCa patients). Mann–Whitney U-test was used to compare the distributions of PSA in different groups. Student's t-test was used to compare the mean values of other continuous variables (age and PV) and Chi-squared test was used to compare the different proportions of categorical variables (DRE result, TRUS result). Receiver operating characteristic curves were used to evaluate the predictive performance of PSA, PSAD, and PSA-AV. A Z-test was performed to compare the differences among area under the receiver operating characteristic curves (AUCs) of PSA, PSAD, and PSA-AV. Additionally, a PSA cutoff of 10.0 ng ml⁻¹, PSAD cutoff of 0.15, and PSA-AV of 400 were compared with each other in the different age groups and different PV groups. The high-grade PCa was defined as patients with a Gleason score ≥8 according to the CUA guideline. A two-sided test with P = 0.05 was used. All statistical analyses were performed using SPSS 19.0 (Statistical Product and Service Solutions, IBM Corporation, Armonk, NY, USA).

RESULTS

A total of 2133 patients were included in the study and 947 (44.4%) were diagnosed with PCa. The characteristics of the study population and the stratified subgroup (PSA ranging from 2.0 ng ml⁻¹ to 20.0 ng ml⁻¹) are shown in Table 1. In the study cohort and its subgroup with PSA ranging from 2.0 ng ml⁻¹ to 20.0 ng ml⁻¹, the mean age, PSA, and positive rates of DRE result and TRUS result were statistically higher in men diagnosed with PCa than that in men without PCa whereas the mean PV was lower in PCa group (all P < 0.05).

The discriminative performance of PSA, PSAD, and PSA-AV for predicting PCa and high-grade PCa was evaluated in the study cohort and its subgroup (Table 2). When predicting PCa, the AUCs of PSAD and PSA-AV were 0.864 and 0.851, respectively, which indicated that both performed better than PSA (AUC = 0.805; P < 0.05). While

Table 1: Characteristics of the study cohort

| Variables | Overall | All PSA | PSA: 2.0–20.0 ng ml⁻¹ |
|-----------|---------|---------|-----------------------|
| Patients (n) | 2133 | 947 | 1186 |
| Age at the time of biopsy (year) | | | |
| Mean (s.d.) | 70.85 (8.7) | 73.0 (8.4) | 69.2 (8.6) |
| Median (IQR) | 71.0 (65.0–77.0) | 74.0 (68.0–79.0) | 69.0 (63.0–76.0) |
| tPSA at the time of biopsy (ng ml⁻¹) | | | |
| Mean (s.d.) | 19.9 (3.5) | 41.4 (4.0) | 11.0 (2.1) |
| Median (IQR) | 14.6 (9.3–33.1) | 32.9 (14.7–100.0) | 10.9 (7.5–16.3) |
| PV (ml) | | | |
| Mean (s.d.) | 53.4 (26.6) | 47.2 (26.0) | 58.3 (26.0) |
| Median (IQR) | 48.0 (35.0–65.0) | 40.4 (30.0–57.0) | 53.6 (40.0–70.9) |
| DRE*, n (%) | | | |
| Positive | 588 (27.6) | 483 (51.0) | 105 (8.9) |
| Missing | 98 (4.6) | 38 (4.0) | 60 (5.1) |
| TRUS (nodule)†, n (%) | | | |
| Positive | 1070 (50.2) | 661 (69.8) | 409 (34.5) |
| Missing | 81 (3.8) | 40 (4.2) | 41 (3.5) |
| Biopsy results, n (%) | | | |
| Positive | 947 (44.4) | / | / |
| Missing | 13 (0.6) | 13 (1.4) | / |
| Gleason score, n (%) | | | |
| ≤6 | 198 (9.3) | 198 (20.9) | / |
| 7 | 385 (18.0) | 385 (40.7) | / |
| ≥8 | 351 (16.5) | 351 (37.1) | / |
| Missing | 13 (0.6) | 13 (1.4) | |
in patients with PSA ranging from 2.0 ng ml\(^{-1}\) to 20.0 ng ml\(^{-1}\), the superiority of PSAD and PSA-AV was more obvious (AUC = 0.768 for PSAD and 0.737 for PSA-AV vs. 0.619 for PSA; P < 0.05). PSAD seemed to perform slightly better than PSA-AV while the difference between their AUCs did not reach statistical significance. When predicting high-grade PCa (Gleason score ≥8), there was no significant difference among the AUCs of PSA, PSAD, and PSA-AV in the study cohort and its subgroup. The ROC curves are shown in Figure 1. In addition, the same analysis was also performed in predicting PCa with Gleason score ≥7, which showed that PSAD and PSA-AV both outperformed PSA in the study cohort and its subgroup (P < 0.05) (Supplementary Table 1).

The sensitivities, specificities, positive predictive values, and negative predictive values of PSA, PSAD, and PSA-AV at different cutoffs are shown in Table 3. As the PSA-AV cutoff increased, the sensitivity increased from 93.7% to 99.8% and the specificity decreased from 40.0% to 2.1%. Then, we calculated the Youden's indexes of different PSA-AV cutoffs (<400, <500, <700, <800, and <1200) and found that the cutoff of <400 performed best among them. The predictive ability was comparable to the commonly used prostate biopsy indication in Chinese (PSAD ≥0.15) and better than PSA ≥10.0 ng ml\(^{-1}\) for its higher positive predictive value (55.5% vs 32.2%).

The numbers of PCa patients detected and missed using 3 predictors were calculated and compared. For example, using a PSA-AV cutoff of <400 led to 78 more biopsies and detecting 56 more cancer cases in comparison with PSA ≥10.0 ng ml\(^{-1}\). We also compared the misdirection rate of difference of PSA-AV <400, PSAD ≥0.15, and PSA ≥10.0 ng ml\(^{-1}\) and the result (Table 4) turned out that both using PSA-AV <400 and PSAD ≥0.15 would have missed fewer PCa patients than using PSA ≥10.0 ng ml\(^{-1}\) (P < 0.05).

The sensitivity and specificity value changes within different age and PV groups are listed in Table 5 and 6. Comparing to PSA cutoff of 10 ng ml\(^{-1}\), A PSA-AV cutoff of 400 had a greater sensitivity in younger patients (age below 70 years) and greater specificity in older patients (age over 70 years). Meanwhile, a PSA-AV cutoff of 400 had a greater sensitivity in patients with small-to-moderate prostate (PV ≤65 ml) and greater specificity in patients with large prostate (PV >65 ml).

**DISCUSSION**

To the best of our knowledge, this is the first study to evaluate PSA-AV in a Chinese prostate biopsy population. First, we calculated the PSA-AV score of our patients and compared the PCA predictive performance of PSA, PSAD, and PSA-AV. Second, we evaluated the diagnostic parameters of PSA-AV at different cutoffs and found an appropriate cutoff value for the Chinese prostate biopsy population. Finally, we compared the cancer missing rate of PSA, PSAD, and PSA-AV at their certain cutoffs.

Since PSA is highly organ specific, rather than cancer specific, several benign conditions (elder age, benign prostate hyperplasia, and inflammation of the prostate) may also cause the elevation of serum PSA level. Therefore, PSA had a low specificity ranging from 10% to 30% at its usual cutoff (normally 4.0 ng ml\(^{-1}\)) throughout different studies and this would cause overdiagnosis and overbiopsy. PSAD was applied to bring the influence of PV into consideration while making the decision of prostate biopsy. Although it was not recommended in EAU guideline, PSAD is still recommended as a biopsy indication in Chinese guideline with the cutoff value of 0.15 ng ml\(^{-1}\). Especially for patients with relatively low PSA level (e.g., 2–10 ng ml\(^{-1}\) in Caucasians and 2.0–20.0 ng ml\(^{-1}\) in Chinese), PSAD had a better performance than PSA in predicting PCa.

PSA-AV was developed by Patel et al.\(^{18}\) to incorporate PSA, age, and PV into an easily calculated score; in their training and validation study, they noticed that PSA-AV performed better than PSA in predicting PCa. Another study also showed that the predicting performance of PSA-AV was comparable to that of PSAD. In the current study, our results showed the AUCs of PSAD and PSA-AV were 0.864 and 0.851, respectively, both performed better than PSA (AUC = 0.805; P < 0.05).
The superiority was more remarkable in patients with PSA ranging from 2.0 to 20.0 ng ml\(^{-1}\). These results were in parallel with the former two studies.\(^{18,19}\) However, while predicting high-grade PCa, we did not observe difference among PSA, PSAD, and PSA-AV in our study. This might attribute to PSA per tumor volume decreases with increasing tumor grade according to a recent study.\(^{33}\) Moreover, although there seemed to be no obvious advantage to calculate PSA-AV while we already have PSAD, we performed additional analysis in 509 biopsy patients with PSA 4–10 ng ml\(^{-1}\) and showed that an extra 8% of unnecessary biopsies could be spared in this subgroup while combining PSA-AV with PSAD in prebiopsy diagnosis (Supplementary Figure 1). The trade-off of combining 3 predictors would be 3 missed cancer cases (missing rate of 0.6%) while TRUS and DRE results are applied together.

### Table 3: Predictive values of prostate-specific antigen-age volume, prostate-specific antigen density and prostate-specific antigen

| Variable          | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------|----------------|----------------|---------|---------|
| PSA-AV <400       | 93.7           | 40.0           | 55.5    | 88.8    |
| PSA-AV <500       | 95.8           | 27.2           | 51.2    | 89.0    |
| PSA-AV <700       | 98.3           | 12.0           | 44.1    | 90.0    |
| PSA-AV <800       | 99.0           | 9.53           | 46.6    | 92.6    |
| PSA-AV <1200      | 99.6           | 3.37           | 45.1    | 90.9    |
| PSA-AV <1600      | 99.8           | 2.1            | 44.9    | 92.6    |
| PSAD              |                |                |         |         |
| ≥0.10             | 98.7           | 11.7           | 47.2    | 92.1    |
| ≥0.15             | 95.8           | 32.0           | 52.9    | 90.5    |
| ≥0.20             | 92.1           | 51.1           | 60.1    | 89.0    |
| PSA (ng ml\(^{-1}\)) ≤4.00 | 99.7           | 4.8            | 23.6    | 98.2    |
| PSA-AV <400       | 93.7           | 41.6           | 32.2    | 95.7    |

PSA: prostate-specific antigen; PSA-AV: prostate-specific antigen-age volume; PSAD: prostate-specific antigen density; PPV: positive predictive value; NPV: negative predictive value

### Table 4: Detection of prostate cancer according to different tests

| Cancer missed | Patients (n) | Missed cases (n) | P       |
|---------------|-------------|------------------|---------|
| PSA-AV ≥400   | 534         | 60               | 3.0×10\(^{-4}\) |
| PSA <0.15     | 418         | 39               | 2.2×10\(^{-5}\) |
| PSA <10.0 ng ml\(^{-1}\) ≤4.00 | 612         | 116              |         |

The P values were calculated using Chi-square test to test whether there is any significant difference of the cancer missing rate (or detection rate) between PSA-AV or PSAD and PSA. PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; PSA-AV: prostate-specific antigen-age volume

### Table 5: Sensitivity and specificity of various cutoff methods in different age groups

| Variable          | Total biopsies (n) | Cancers detected (n) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------|--------------------|----------------------|----------------|----------------|---------|---------|
| Age <60 years     |                    |                      |                |                |         |         |
| PSA ≥10 ng ml\(^{-1}\) | 151           | 64                   | 92.8           | 42.4           | 42.4    | 92.8    |
| PSAD ≥0.15        | 187               | 68                   | 98.6           | 21.2           | 36.4    | 97.0    |
| PSA-AV <400       | 194               | 68                   | 98.6           | 16.6           | 35.1    | 96.2    |
| Age 60–69 years   |                    |                      |                |                |         |         |
| PSA ≥10 ng ml\(^{-1}\) | 443           | 198                  | 84.6           | 45.3           | 44.7    | 84.9    |
| PSAD ≥0.15        | 531               | 227                  | 97.0           | 32.1           | 42.2    | 95.4    |
| PSA-AV <400       | 505               | 225                  | 96.2           | 37.5           | 44.6    | 94.9    |
| Age ≥70 years     |                    |                      |                |                |         |         |
| PSA ≥10 ng ml\(^{-1}\) | 923           | 566                  | 88.3           | 38.7           | 61.3    | 75.0    |
| PSA-AV <400       | 933               | 611                  | 95.3           | 34.4           | 65.5    | 87.0    |

PSA: prostate-specific antigen; PSA-AV: prostate-specific antigen-age volume; PSAD: prostate-specific antigen density; PPV: positive predictive value; NPV: negative predictive value

Another issue that might be of interest was the difference of performance between PSA-AV and logistic regression models combining independent predictors (e.g., PSA, age, PV, DRE, and TRUS findings).\(^{14}\) In order to illustrate this issue, we divided our cohort into two parts (one with 1067 and another with 1066 patients) and built a logistic model based on PSA, age, and PV in 1067 patients. Then, we validated this logistic model in the other 1066 patients and showed an AUC of 0.855 in predicting PCa in the validation cohort (while PSA-AV had an AUC of 0.851, \(P_{\text{AUC compare}} = 0.78\)). The model could be improved with an AUC of 0.880 if DRE (normal or abnormal) and TRUS (normal or abnormal) are added, which was better than PSA-AV (\(P_{\text{AUC compare}} = 0.02\)). The AUC of PSA in our cohort was 0.805, which was relatively high compared with reported Western studies (mostly slightly above 0.5). This finding might be attributable to the fact that the current study was based on a biopsy population at higher risk for PCa (a positive biopsy rate of 44.4%). For example, some of the patients came to the urology department because of elevated PSA while others are seeking help for their urinary symptoms. This reason might also be the explanation of the relatively high AUCs of PSAD, PSA-AV, and the logistic models mentioned above.

In a diagnostic study, Youden's index (sensitivity + specificity−1) is used to determine the cutoff value of a diagnosis test. Briefly, Youden's Index values are larger when both sensitivity and specificity are higher, which indicates that the best cutoff has been identified.\(^{33}\) In order to compare with former studies, we calculated the Youden's indexes of different PSA-AV cutoffs (<400, <500, <700, <800, and <1200) and found that PSA-AV <400 performed best among them. At this cutoff, the sensitivity was 93.7% and the specificity was 40.0%. In former studies, at the cutoff of 700, the sensitivity ranged from 85% to 95% while the specificity ranged from 35% to 15%. The predictive performance in the current study was better than that of all previous studies; thus, we recommend a PSA-AV cutoff of 400 in Chinese population.\(^{18-20}\)

Our data showed that in age <70-year group, the sensitivities of PSA-AV cutoff of 400 ranged from 96.2% to 98.6%, which were better than that of PSA cutoff of 10 ng ml\(^{-1}\) (ranged from 84.6% to 92.8%). While in age ≥70-year group, the specificity of PSA-AV cutoff of 400 was 47.8%, which was better than that of PSA cutoff of 10 ng ml\(^{-1}\) (38.7%). In patients with low-to-moderate PVs (≤65 ml), the sensitivities of PSA-AV ranged from 97.2% to 93.8%, which were better than that of PSA cutoff of 10 ng ml\(^{-1}\) (ranged from 82.2% to 89.3%). While in PV ≥65 ml group, the specificity of PSA-AV cutoff of 400 was 58.3%, which was better than that of PSA cutoff of...
Table 6: Sensitivity and specificity of various cutoff methods in different prostate volume groups

| Variable          | Total biopsies (n) | Cancers detected (n) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------|--------------------|----------------------|-----------------|-----------------|---------|---------|
| PV <35 ml         |                    |                      |                 |                 |         |         |
| PSA ≥10 ng ml⁻¹   | 360                | 268                  | 82.2            | 49.7            | 74.4    | 61.1    |
| PSAD ≥0.15        | 477                | 319                  | 97.9            | 13.7            | 66.9    | 78.1    |
| PSA-AV <400       | 469                | 317                  | 97.2            | 16.9            | 67.6    | 77.5    |
| PV 35–65 ml       |                    |                      |                 |                 |         |         |
| PSA ≥10 ng ml⁻¹   | 676                | 376                  | 89.3            | 47.6            | 55.6    | 85.8    |
| PSAD ≥0.15        | 821                | 408                  | 96.9            | 27.8            | 49.7    | 92.4    |
| PSA-AV <400       | 764                | 395                  | 93.8            | 35.5            | 51.7    | 88.6    |
| PV >65 ml         |                    |                      |                 |                 |         |         |
| PSA ≥10 ng ml⁻¹   | 418                | 149                  | 96.1            | 26.7            | 35.6    | 94.2    |
| PSAD ≥0.15        | 331                | 140                  | 90.3            | 48.0            | 42.3    | 92.1    |
| PSA-AV <400       | 288                | 135                  | 87.1            | 58.3            | 46.9    | 95.1    |

PV: prostate volume; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density. PPV: positive predictive value; NPV: negative predictive value; PSA-AV: prostate-specific antigen-age volume

10 ng ml⁻¹ (26.7%). Thus, in Chinese population, PSA-AV would be a useful tool in ruling out PCa in younger patients (age <70 years) and in patients with a smaller prostate (PV <65 ml). Results from the current study also supported that using a PSA-AV cutoff of 400 performed more stable across stratified groups (with different age and PV) in Chinese population than the cutoff of 700 in Patel’s study in a multi-ethnic population.¹⁸

In the current study, we chose PSA cutoff of 10 ng ml⁻¹ as a comparing cutoff. It was attributed to the difference of PSA “gray zone” in Chinese and Western population as we have mentioned in another study.¹⁶ Evidence from our study and another biopsy cohort from Shanghai showed that the PCa detection rate in patients with PSA at 10–20 ng ml⁻¹ ranged from 29.6% to 36.5%. This detection rate was comparable to the PCa detection rate (34%) in patients with PSA at 4–10 ng ml⁻¹ in Western populations.¹⁷

The current study had several strengths: (i) we provided a comprehensive description of the cancer predictive performance of PSA-AV, PSAD, and PSA in a large Chinese biopsy population; (ii) we found a suitable PSA-AV cutoff of 400 in Chinese population; (iii) a contemporary standard 10-core biopsy was used in most of the population. One limitation of our study is that it is a retrospective study from only one health institute. However, as one of the tertiary health institutes in China, patients from all over the country seek for medical service in our institute. Thus, our study population could partially represent the Chinese population.

CONCLUSIONS

According to our data, the PSA-AV score performed equally with PSAD and was better than PSA in predicting PCa. This indicated that PSA-AV score could be a useful tool for predicting PCa in Chinese population. Especially, it was more sensitive in younger patients and patients with small prostates.

AUTHOR CONTRIBUTIONS

YSW, RN, QD conceived and designed the study. XBW, NZ, and RN performed the experiments. YSW, XBW, and RN analyzed the data. GLJ, YY, SJT, HWJ, and SHM contributed materials and analysis tools. YSW, XBW, and QD wrote the manuscript. All authors have read and approved the final version of the manuscript and agreed with the order of presentation of the authors.

COMPETING INTERESTS

All authors declared no competing interests.

ACKNOWLEDGMENTS

The authors would like to thank all the people who took part in this study. This study was sponsored by the National Natural Science Foundation of China (No. 81402339) to RN, the Clinical Science and Technology Innovation Project of Shanghai Shen Kang Hospital Development Center (No. SHDC12015105) and the National Basic Research Program of China (973 Program, No. 2015CB943003) to QD, and the Scientific Research project supported by Huashan Hospital, Fudan University to YSW (No. 2016QD079).

Supplementary information is linked to the online version of the paper on the Asian Journal of Andrology website.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
3. Ye DW, Li CL. Epidemiological trends of prostate cancer: retrospect and prospect. China Oncol 2007; 17: 177–80.
4. Hising AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60–7.
5. Na YQ, Ye ZQ, Sun YH, Sun G, Huang J, et al. Chinese Urological Association Guidelines 2014 Edition. Beijing: People’s Medical Publishing House; 2014. p. 61. (Book in Chinese).
6. Catalona WJ, Smith DS, Ratliff TL, Dados KM, Coplen DE, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.
7. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Med 2003; 16: 95–101.
8. Gann PH, Ma J, Catalona WJ, Stumper MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002; 167: 2427–34.
9. Lan JS, Cheung YK, Benson MC, Gallopp ET. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. J Urol 2003; 170: 451–6.
10. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167: 103–11.
11. Colleselli D, Bektic J, Schaefer G, Frauscher F, Mitterberger M, et al. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy. BJU Int 2007; 100: 1264–7.
12. Oesterling JE. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860–4.
13. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Pironen T, et al. Free, combined and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–5.
14. Morgan TO, Jacobsen SJ, McCarthy WP, Jacobson DJ, McLeod DG, et al. Age-specific
reference ranges for prostate-specific antigen in black men. *N Engl J Med* 1996; 335: 304–10.

15 Wu YS, Na R, Xu JF, Bai PD, Jiang HW, et al. The influence of prostate volume on cancer detection in the Chinese population. *Asian J Androl* 2014; 16: 482–6.

16 Na R, Wu Y, Xu J, Jiang H, Ding Q. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in the Chinese population. *PLoS One* 2013; 8: e67585.

17 Kao CH. Age-related free PSA, total PSA and free PSA:total PSA ratios: establishment of reference ranges in Chinese males. *Anticancer Res* 1997; 17: 1361–5.

18 Patel S, Issa MM, El-Galley R. Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings. *Urol Clin North Am* 2013; 8: 602–6.

19 Murray NP, Reyes E, Fuentealba C, Orellana N, Morales F, et al. Comparison of the formula of PSA, age, prostate volume and race versus PSA density and the detection of primary malignant circulating prostate cells in predicting a positive initial prostate biopsy in chilean men with suspicion of prostate cancer. *Asian Pac J Cancer Prev* 2015; 16: 5365–70.

20 Ucer O, Yucetas U, Celien I, Toktas G, Muezzinoglu T. Assessment of PSA-age volume score in predicting positive prostate biopsy findings in Turkey. *Int Braz J Urol* 2015; 41: 864–8.

21 Na R, Jiang H, Kim ST, Wu Y, Tong S, et al. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011. *PLoS One* 2012; 7: e49914.

22 Bruno JJ, Armenakas NA, Fracchia JA. Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml. *J Urol* 2007; 177: 1741–4.

23 Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, et al. The prostate cancer prevention trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. *Cancer* 2013; 119: 3007–11.

24 Zheng XY, Xie LP, Wang YY, Ding W, Yang K, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4.0–10.0 ng/mL. *J Cancer Prev Clin Oncol* 2008; 134: 1207–10.

25 Tang P, Du W, Xie K, Deng X, Fu J, et al. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. *Urol Oncol* 2013; 31: 744–8.

26 Beduschi MC, Oestering JE. Prostate-specific antigen density. *Urol Clin North Am* 1997; 24: 323–32.

27 Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. *JAMA* 1993; 270: 948–54.

28 Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. *J Natl Cancer Inst* 2002; 94: 981–90.

29 Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. *BJU Int* 2009; 103: 578–87.

30 Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. *Eur Urol* 2011; 60: 214–22.

31 Lin YR, Wei XH, Uhlman M, Lin XT, Wu SF, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml−1 and 10.1–20.0 ng ml−1: a multicenter study. *Asian J Androl* 2015; 17: 503–7.

32 Teoh JY, Yuen SK, Tsu JH, Wong CK, Ho BS, et al. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. *Asian J Androl* 2017; 19:113–6.

33 Stuchbery RM, Cnero M, Harewood LM, Peters JS, Costello AJ, et al. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. *Oncotarget* 2016; 7: 31384–92.

34 Chiu PK, Robol MJ, Nieboer D, Teoh JY, Yuen SK, et al. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. *Prostate Cancer Prostatic Dis* 2017; 20: 99–104.

35 Galen RS. Application of the predictive value model in the analysis of test effectiveness. *Clin Lab Med* 1992; 2: 685–99.

36 Na R, Ye D, Liu F, Chen H, Qi J, et al. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. *Prostate* 2014; 74: 1569–75.

37 Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World J Urol* 2012; 30: 181–7.
**Supplementary Table 1: Evaluation of the area under the receiver operating characteristic curves of prostate-specific antigen and its derivatives in predicting Gleason ≥7 prostate cancer**

|                       | All PSA | AUC          | Gleason ≥7 PCa (34.5%) | Lower 95% | Upper 95% | P*         |
|-----------------------|---------|--------------|------------------------|-----------|-----------|------------|
| PSA                   | 0.825   | 0.806–0.845  |                        |           |           |            |
| PSADb                 | 0.861   | 0.844–0.878  | 7.5×10⁻³               |           |           |            |
| PSA-AVc               | 0.851   | 0.834–0.869  | 4.9×10⁻²               |           |           |            |

| PSA=2.0–20.0 ng ml⁻¹  | AUC     | Gleason ≥7 PCa (16.4%) | Lower 95% | Upper 95% | P*         |
|-----------------------|---------|------------------------|-----------|-----------|------------|
| PSA                   | 0.615   | 0.573–0.657            |           |           |            |
| PSADb                 | 0.732   | 0.694–0.771            | 3.6×10⁻⁵  |           |            |
| PSA-AVc               | 0.707   | 0.667–0.746            | 1.5×10⁻³  |           |            |

*The P value referred to the significance between PSAD or PSA-AV and PSA.

bPSAD = PSA/PV; PV (ml) = height (cm) × length (cm) × width (cm) × 0.52.

cPSA-AV = age × PV/PSA; PCa: prostate cancer; PSA: prostate-specific antigen;
PSAD: prostate-specific antigen density; PSA-AV: prostate-specific antigen-age volume;
AUC: area under the receiver operating characteristic curve; PV: prostate volume
Supplementary Figure 1: Number of unnecessary biopsies spared by combining PSAD and PSA-AV. ROC: receiver operating characteristic curve; tPSA: total prostate-specific antigen; PSA-AV: prostate-specific antigen-age volume; PSAD: prostate-specific antigen density.